1. Atazanavir-induced unconjugated hyperbilirubinemia prevents vascular hyporeactivity during experimental human endotoxemia
- Author
-
Mirrin J. Dorresteijn, Douwe Dekker, Jelle Zwaag, Suzanne Heemskerk, Hennie M.J. Roelofs, Paul Smits, Johannes G. van der Hoeven, Frank A.D.T.G. Wagener, and Peter Pickkers
- Subjects
antioxidant ,heme oxygenase system ,atherosclerosis ,bilirubin ,inflammation ,endothelial dysfunction ,Immunologic diseases. Allergy ,RC581-607 - Abstract
ObjectiveInflammation-induced free radical release is important in the pathogenesis of several diseases, including atherosclerosis and sepsis. Heme oxygenase (HO) breaks down heme into carbon monoxide, iron, and biliverdin. Biliverdin IXα is directly converted to bilirubin by biliverdin reductase. Unconjugated bilirubin is a powerful antioxidant, and elevated levels have beneficial effects in preclinical models and human cardiovascular disease. However, its impact during acute inflammation in humans is unknown. In the present study, we investigated the impact of atazanavir-induced (unconjugated) hyperbilirubinemia on antioxidant capacity, inflammation, and vascular dysfunction in human experimental endotoxemia.Approach and resultsFollowing double-blinded four-day treatment with atazanavir 2dd300 mg (or placebo), twenty healthy male volunteers received 2 ng/kg Escherichia coli lipopolysaccharide intravenously. Blood was drawn to determine the bilirubin levels, antioxidant capacity, and cytokine response. It was demonstrated that following atazanavir treatment, total bilirubin concentrations increased to maximum values of 4.67 (95%CI 3.91-5.59) compared to 0.82 (95%CI 0.64-1.07) mg/dL in the control group (p
- Published
- 2023
- Full Text
- View/download PDF